Considering that the expression level of GLT1 in astrocytes is decreased in ALS patients due to dysfunction of GLT1 splicing [47], it is possible that these changes may be caused by changes in the packaging of EVs and targeting astrocytes. Here, SLC1A2 is linked to amyotrophic lateral sclerosis.